Subtopic Deep Dive
Antibiotic Resistance in Melioidosis
Research Guide
What is Antibiotic Resistance in Melioidosis?
Antibiotic resistance in melioidosis refers to the intrinsic and acquired mechanisms in Burkholderia pseudomallei that confer resistance to key antibiotics like ceftazidime, carbapenems, aminoglycosides, and macrolides, complicating treatment of this opportunistic infection.
Burkholderia pseudomallei, the causative agent of melioidosis, exhibits multidrug resistance through efflux pumps and other mechanisms (Rhodes and Schweizer, 2016; 370 citations). Efflux-mediated resistance to aminoglycosides and macrolides was demonstrated using Tn5-OT182 mutagenesis (Moore et al., 1999; 296 citations). Over 10 key papers since 1999 profile resistance evolution and treatment implications, with Currie et al. (2010; 751 citations) emphasizing early diagnosis and appropriate antibiotics for survival.
Why It Matters
Rising ceftazidime and carbapenem resistance in B. pseudomallei drives poor treatment outcomes in melioidosis-endemic regions like Southeast Asia and Northern Australia (Currie, 2015; 334 citations). Efflux pumps enable intrinsic resistance, necessitating prolonged intensive and eradication phases with drugs like meropenem (Schweizer, 2012; 261 citations). Genomic surveillance and pharmacodynamic modeling inform optimized regimens, reducing mortality from 40% in untreated cases (Currie et al., 2010). Rhodes and Schweizer (2016) highlight how understanding Burkholderia resistance mechanisms guides novel therapeutic strategies amid increasing global spread.
Key Research Challenges
Efflux Pump Overexpression
B. pseudomallei uses efflux pumps for intrinsic resistance to aminoglycosides, macrolides, and β-lactams. Tn5-OT182 mutagenesis identified efflux mutants with restored susceptibility (Moore et al., 1999). Inhibiting these pumps remains challenging for clinical translation (Rhodes and Schweizer, 2016).
Ceftazidime/Carbapenem Resistance
Emerging resistance to first-line agents ceftazidime and meropenem during therapy worsens prognosis. Prolonged treatment selects for resistant subpopulations (Schweizer, 2012). Surveillance data show variable regional rates complicating empiric therapy (Currie, 2015).
Genomic Surveillance Gaps
Tracking resistance evolution requires whole-genome sequencing of clinical isolates. Limited data on mobile elements hinder prediction models (Rhodes and Schweizer, 2016). Integrating pharmacodynamics with genomics for personalized regimens is underdeveloped (Wiersinga et al., 2018).
Essential Papers
The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study
Bart J. Currie, Linda Ward, Allen Cheng · 2010 · PLoS neglected tropical diseases · 751 citations
Melioidosis should be seen as an opportunistic infection that is unlikely to kill a healthy person, provided infection is diagnosed early and resources are available to provide appropriate antibiot...
Melioidosis
W. Joost Wiersinga, Harjeet Singh Virk, Alfredo G. Torres et al. · 2018 · Nature Reviews Disease Primers · 620 citations
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei
W. Joost Wiersinga, Tom van der Poll, Nicholas J. White et al. · 2006 · Nature Reviews Microbiology · 582 citations
Antibiotic resistance in Burkholderia species
Katherine A. Rhodes, Herbert P. Schweizer · 2016 · Drug Resistance Updates · 370 citations
Burkholderia Type VI Secretion Systems Have Distinct Roles in Eukaryotic and Bacterial Cell Interactions
Sandra Schwarz, T. Eoin West, Frédéric Boyer et al. · 2010 · PLoS Pathogens · 366 citations
Bacteria that live in the environment have evolved pathways specialized to defend against eukaryotic organisms or other bacteria. In this manuscript, we systematically examined the role of the five...
Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment
Bart J. Currie · 2015 · Seminars in Respiratory and Critical Care Medicine · 334 citations
Infection with Burkholderia pseudomallei can result in asymptomatic seroconversion, a single skin lesion that may or may not heal spontaneously, a pneumonia which can be subacute or chronic and mim...
Efflux-Mediated Aminoglycoside and Macrolide Resistance in <i>Burkholderia pseudomallei</i>
Richard A. Moore, David DeShazer, Shauna L. Reckseidler et al. · 1999 · Antimicrobial Agents and Chemotherapy · 296 citations
ABSTRACT Burkholderia pseudomallei , the causative agent of melioidosis, is intrinsically resistant to a wide range of antimicrobial agents including β-lactams, aminoglycosides, macrolides, and pol...
Reading Guide
Foundational Papers
Start with Moore et al. (1999) for efflux-mediated resistance discovery via mutagenesis; Currie et al. (2010) for clinical epidemiology stressing antibiotic timing; Rhodes and Schweizer (2016) for broad Burkholderia mechanisms overview.
Recent Advances
Study Schweizer (2012) for melioidosis-specific implications; Wiersinga et al. (2018; 620 citations) for updated pathogenesis and treatment; Currie (2015) for evolving concepts including resistance trends.
Core Methods
Core techniques include Tn5-OT182 mutagenesis (Moore et al., 1999), MIC susceptibility testing (Currie et al., 2010), whole-genome sequencing for resistance genes (Rhodes and Schweizer, 2016), and pharmacodynamic modeling for regimen optimization (Schweizer, 2012).
How PapersFlow Helps You Research Antibiotic Resistance in Melioidosis
Discover & Search
Research Agent uses searchPapers('antibiotic resistance Burkholderia pseudomallei efflux') to find Moore et al. (1999), then citationGraph reveals 296 citing papers on efflux mechanisms, and findSimilarPapers expands to Rhodes and Schweizer (2016) for comprehensive Burkholderia resistance reviews.
Analyze & Verify
Analysis Agent applies readPaperContent on Schweizer (2012) to extract resistance implications, verifies claims via verifyResponse (CoVe) against Currie et al. (2010), and runs runPythonAnalysis for statistical verification of resistance rates from Darwin study data, with GRADE grading for evidence quality in treatment guidelines.
Synthesize & Write
Synthesis Agent detects gaps in ceftazidime resistance surveillance via contradiction flagging across Wiersinga et al. (2018) and Currie (2015), while Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 10+ references, latexCompile for PDF output, and exportMermaid for resistance mechanism diagrams.
Use Cases
"Model efflux pump resistance rates in B. pseudomallei isolates from melioidosis cases"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of resistance frequencies from Moore et al. 1999 and Currie 2010 data) → matplotlib plot of MIC distributions.
"Draft LaTeX review on carbapenem resistance evolution in melioidosis"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Rhodes 2016, Schweizer 2012) → latexCompile → PDF with embedded resistance timeline.
"Find code for B. pseudomallei genomic resistance analysis"
Research Agent → paperExtractUrls (Wiersinga 2018 supplements) → paperFindGithubRepo → githubRepoInspect → Python scripts for efflux gene annotation and resistance prediction.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ melioidosis resistance papers via searchPapers → citationGraph → structured report with GRADE-scored evidence on efflux mechanisms (Moore et al., 1999). DeepScan applies 7-step analysis with CoVe checkpoints to verify pharmacodynamic models from Schweizer (2012). Theorizer generates hypotheses on T6SS contributions to resistance persistence from Schwarz et al. (2010).
Frequently Asked Questions
What defines antibiotic resistance in melioidosis?
Resistance in Burkholderia pseudomallei involves intrinsic efflux pumps against aminoglycosides/macrolides (Moore et al., 1999) and acquired mechanisms against ceftazidime/carbapenems (Schweizer, 2012), requiring 10-14 day intensive therapy followed by eradication.
What are key methods for studying resistance?
Tn5-OT182 mutagenesis identifies efflux mutants (Moore et al., 1999); MIC testing and genomic sequencing track evolution (Rhodes and Schweizer, 2016); pharmacodynamic modeling predicts outcomes (Currie, 2015).
What are landmark papers?
Currie et al. (2010; 751 citations) profiles Darwin cohort emphasizing antibiotics; Moore et al. (1999; 296 citations) demonstrates efflux resistance; Rhodes and Schweizer (2016; 370 citations) reviews Burkholderia mechanisms.
What open problems persist?
Efflux pump inhibitors lack clinical trials; real-time genomic surveillance is regionally limited; T6SS roles in resistance persistence need clarification (Schwarz et al., 2010; Wiersinga et al., 2018).
Research Burkholderia infections and melioidosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antibiotic Resistance in Melioidosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers